Neurocrine Biosciences, Inc. (NBIX) earnings: date, estimates, results and stock reactions
Next earnings: Q4 FY2026 on 2027-02-10 (expected, after the close). EPS estimate 2.07, revenue estimate 1.09B.
Over the last 12 reports the stock moved 8.3% on average (either way), rising 6 times and falling 6. EPS beat estimates 7 of 12 times; revenue 8 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-02 | 3.29 | 1.91 | +72.3% | 1.12B | 1.04B | +12.8% |
| Q2 FY2026 | 2026-07-30 | 2.85 | 1.85 | +54.1% | 959.0M | 890.3M | -7.7% |
| Q1 FY2026 | 2026-05-05 | 1.91 | 1.22 | +56.6% | 814.5M | 768.3M | +9.7% |
| Q4 FY2025 | 2026-02-11 | 1.88 | 1.80 | +4.4% | 805.5M | 790.5M | -10.6% |
| Q3 FY2025 | 2025-10-28 | 2.04 | 1.58 | +29.1% | 794.9M | 806.8M | -7.3% |
| Q2 FY2025 | 2025-07-30 | 1.06 | 0.98 | +8.2% | 687.5M | 746.4M | -4.4% |
| Q1 FY2025 | 2025-05-05 | 0.08 | 0.54 | -85.0% | 572.6M | 559.6M | +8.4% |
| Q4 FY2024 | 2025-02-06 | 1.00 | 1.62 | -38.3% | 627.7M | 629.4M | -18.9% |